The Pathway for New Cancer Drug Access in Canada
Cancer treatment has evolved significantly over the past decade with the emergence of a multitude of new treatments across cancer types. Alongside the pace of drug discovery, the cost of cancer drugs has also increased. In the face of this growth in development and spending, it is crucial to have an...
Main Authors: | Joanna Gotfrit, William Dempster, Johanne Chambers, Paul Wheatley-Price |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/29/2/41 |
Similar Items
-
Determinants of the Cancer Drug Funding Process in Canada
by: Joanna Gotfrit, et al.
Published: (2022-03-01) -
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action
by: Sandeep Sehdev, et al.
Published: (2024-03-01) -
Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021
by: Sandeep Sehdev, et al.
Published: (2022-03-01) -
Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025
by: Richard Lech, et al.
Published: (2022-10-01) -
Access in all areas? A round up of developments in market access and health technology assessment: part 3
by: Alice Beattie, et al.
Published: (2024-02-01)